Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Mitochondrion outer membrane |
Domain |
PF13516 Leucine Rich repeat |
Function |
Participates in antiviral signaling. Acts as a negative regulator of MAVS-mediated antiviral responses, through the inhibition of the virus-induced RLH (RIG-like helicase)-MAVS interaction (PubMed:18200010). Instead, promotes autophagy by interacting with TUFM and subsequently recruiting the autophagy-related proteins ATG5 and ATG12 (PubMed:22749352). Regulates also MAVS-dependent NLRP3 inflammasome activation to attenuate apoptosis (PubMed:27393910). Has no inhibitory function on NF-kappa-B signaling pathway, but enhances NF-kappa-B and JUN N-terminal kinase dependent signaling through the production of reactive oxygen species (PubMed:18219313). |
Biological Process |
GO:0001818 negative regulation of cytokine production GO:0001819 positive regulation of cytokine production GO:0002218 activation of innate immune response GO:0002221 pattern recognition receptor signaling pathway GO:0002683 negative regulation of immune system process GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002753 cytoplasmic pattern recognition receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002831 regulation of response to biotic stimulus GO:0002832 negative regulation of response to biotic stimulus GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0009615 response to virus GO:0030522 intracellular receptor signaling pathway GO:0031348 negative regulation of defense response GO:0031349 positive regulation of defense response GO:0032102 negative regulation of response to external stimulus GO:0032479 regulation of type I interferon production GO:0032480 negative regulation of type I interferon production GO:0032606 type I interferon production GO:0032608 interferon-beta production GO:0032635 interleukin-6 production GO:0032648 regulation of interferon-beta production GO:0032675 regulation of interleukin-6 production GO:0032688 negative regulation of interferon-beta production GO:0032715 negative regulation of interleukin-6 production GO:0039528 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039529 RIG-I signaling pathway GO:0039531 regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway GO:0039532 negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway GO:0039535 regulation of RIG-I signaling pathway GO:0039536 negative regulation of RIG-I signaling pathway GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045824 negative regulation of innate immune response GO:0048525 negative regulation of viral process GO:0050687 negative regulation of defense response to virus GO:0050688 regulation of defense response to virus GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0050777 negative regulation of immune response GO:0050792 regulation of viral process GO:0051607 defense response to virus GO:0098542 defense response to other organism GO:0098586 cellular response to virus GO:1902532 negative regulation of intracellular signal transduction |
Molecular Function | - |
Cellular Component |
GO:0005741 mitochondrial outer membrane GO:0019867 outer membrane GO:0031968 organelle outer membrane |
KEGG |
hsa04621 NOD-like receptor signaling pathway hsa04622 RIG-I-like receptor signaling pathway |
Reactome |
R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways |
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between NLRX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of NLRX1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of NLRX1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of NLRX1 in various data sets.
|
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRX1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of NLRX1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between NLRX1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | NLRX1 |
Name | NLR family member X1 |
Aliases | NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ...... |
Chromosomal Location | 11q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting NLRX1 collected from DrugBank database. |
There is no record. |